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The differentiation  of resting  B lymphocytes to Ig secretion involves several 
sequential  steps  regulated  by antigen,  T  lymphocytes, and  macrophages.  The 
requirement for T  cells may in some cases be replaced by lymphokines secreted 
upon T  cell activation  (1, 2).  A number of distinct T  cell-derived lymphokines 
have been described (3-9) that directly regulate the growth and  maturation  of 
B cells. These include  IL-2 (3,  4),  IFN-3, (5, 6), and at least two additional,  yet 
less well-characterized molecules, B cell stimulating factor, (also known as B cell 
growth factor, BCGF or BSF-1) ~ (7, 8), and B cell differentiation factor (BCGF- 
II or BCDF) (9).  BSF-1  was originally  (7)  described as a  factor that  stimulated 
proliferation of B cells in conjunction with a submitogenic concentration of anti- 
Ig.  Recent studies (10,  1 1) have shown that  semipurified BSF-1  acts on resting 
B  cells,  facilitating  their  entry  into  S  phase  upon  subsequent  interaction  with 
anti-Ig. These studies (1 1) indicate that BSF-1 might actually be a differentiation 
factor, and they further suggest that BSF-1 may not have growth factor activity. 
We have purified BSF-1 to homogeneity from culture supernatants of mitogen- 
activated EL4 thymoma cells. We used the proliferation of highly purified splenic 
B cells in the presence ofanti-IgM as an assay in our purification procedure. The 
purification  was  also  monitored  for  additional  lymphokines  using  the  factor- 
dependent  cell  lines  CTLL-2  and  FDC-P2.  Interestingly,  fractions  containing 
BSF-1 always contained stimulatory activity for both IL-2- and  IL-3-dependent 
cell lines, even though these fractions were devoid of IL-2 and IL-3 protein. N- 
terminal  amino  acid  sequencing  of  homogeneous  BSF-1  revealed  a  unique 
protein sequence completely different from that of murine  IL-2 or IL-3.  Based 
on  these  results,  we conclude that  BSF-1  is both a  growth and  differentiation 
factor that may have biologic effects beyond the B lymphocyte compartment. 
Materials and Methods 
Mice.  Female  C57BL/6J  mice  were  obtained  from  The Jackson  Laboratory,  Bar 
Harbor, ME, and were used at 8-12 wk of age. 
Abbreviations used in this paper:  BSF-  1, B cell-stimulating factor; DIEA-Ac, N,N-diisopropyleth- 
ylamine; TFA, trifluoroacetic acid; TMS-silica, trimethylsilyl-silica. 
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Preparation ofB Lymphocytes.  Mice were pretreated  with intraperitoneal  injections of 
T24 rat anti-mouse Thy-1 mAb (12). 3 d later, the spleens were removed and treated in 
vitro  with  a  cocktail  of T24,  GK1.5  rat  anti-mouse  L3T4  mAb,  rabbit  anti-mouse 
thymocyte serum (liver- and bone marrow-absorbed) and rabbit complement (Pel-Freeze 
Biologicals, Rogers, AR). The T cell-depleted spleen cells were then passed over Sephadex 
G10 to remove adherent cells, and the B lymphocytes were positively selected by panning 
on petri dishes coated with goat anti-mouse IgM (Cooper Biomedical, Inc., Malvern, PA). 
Purified B cells contained undetectable  levels of T  cells and >98%  B cells as judged by 
flow cytometer analysis (Epics-C; Coulter  Electronics,  Inc., Hialeah,  FL) using T24 and 
anti-L3T4 rat mAb, followed by FITC-conjugated rabbit anti-rat  Ig (Becton Dickinson 
hnmunocytometry Systems, Mountain View, CA) to detect T  cells, and FITC-conjugated 
rabbit anti-mouse IgM to detect B cells.  In addition, such a  B cell population was found 
to be completely unresponsive to the T  cell mitogen, Con A, but retained full responsive- 
ness to the B cell mitogen LPS. 
Cell Lines.  EL4 thymoma cells were maintained in RPMI-1640 supplemented with 5% 
FCS, 50 U/ml penicillin, 50 ~g/ml streptomycin and 2 mM glutamine. For the production 
of lymphokine-containing supernatants,  EL4 cells were stimulated in serum-free medium 
with  1%  PHA  (PHA-M;  Difco  Laboratories,  Detroit  MI)  and  10  ng/ml  PMA  (Sigma 
Chemical Co., St.  Louis, MO). Cell-free supernatant was collected by centrifugation after 
24 h. 
CTLL-2 an IL-2-dependent murine T  cell line (13) was maintained in Click's medium 
(Atlick Associates,  River Falls,  WI) containing  10%  FCS,  50  U/ml penicillin,  50 ug/ml 
streptomycin, and  100 U/ml of IL-2 from a supernatant of rat spleen cells cultured 24 h 
with Con A (Pharmacia Fine Chemicals, Piscataway, N  J). 
FDC-P2,  a  factor-dependent  murine  cell  line  derived  from  long-term  bone marrow 
cultures  (14)  was  maintained  in  RPMI-1640  containing  20%  horse  serum,  50  U/ml 
penicillin,  50 #g/ml streptomycin, 50 #M 2-ME, and  10% WEHI-3 cell line-conditioned 
medium. 
32D, an IL-3-dependent murine hemopoietic cell line (15) was kindly provided by Dr. 
James Watson (Auckland Medical School, Auckland,  New Zealand) and was maintained 
in Click's medium containing 10% WEHI-3 cell line-conditioned medium, 10% FCS, and 
antibiotics. 
Cellular Assays.  BSF-1  was  assayed  by  its  ability  to  stimulate  the  proliferation  of 
purified B cells in the presence of a submitogenic concentration of goat anti-mouse IgM 
(7).  B cells were cultured (105  cells/culture)  in  200 #1 containing 3-5 #g/ml of affinity- 
purified goat anti-mouse IgM (Cooper Biomedical, Inc.) and serial dilutions of test sample. 
After  72  h,  cultures  received  2.0  #Ci  of [3H]thymidine  (75  Ci/mmol,  New  England 
Nuclear, Boston, MA) for 6 h, were harvested onto glass fiber filters,  and incorporation 
of radioactivity was measured. 
All proliferation assays using factor-dependent cell lines were performed using 2 x  10  '~ 
cells/culture  in  100  ul  of Click's  medium  containing  10%  FCS,  antibiotics,  and  test 
samples.  After 24 h, cultures  received 2.0 ~tCi of [3H]thymidine (75 Ci/mmol) for 6  h, 
were harvested onto glass fiber filters,  and incorporation of radioactivity was measured. 
For all proliferation assays, 1 U of activity was defined as the amount of lymphokine that 
induced 50% of maximal proliferation in 100 #1 cultures. For example, if a sample induced 
50% of maximal proliferation at a dilution of 1:20, then  1 U  was said to be contained in 
one-twentieth of ! 00 ul, or 5 #1, and the sample said to contain 200 U/ml. 
Lymphokines.  A  mouse IL-2 cDNA was cloned from a library prepared from LBRM- 
33 lymphoma cell mRNA by Immunex Corporation and was expressed in yeast using the 
yeast a  factor promoter and leader sequences to direct synthesis and secretion (16). rIL- 
2 was purified to homogeneity as previously described (17), and had a specific activity of 
10  ~ U/rag. 
A  mouse  IL-3 cDNA was also  cloned  from  the  above-detailed  library  by  Immunex 
Corporation, expressed  in yeast, and  resultant  rIL-3 was purified  to homogeneity (18). 
Purified murine rIL-3 had sp act of 1.1  x  101° U/mg. 
BSF-1 Pur~cation.  BSF-1 was purified from 71.5 liters of supernatant from PHA and GRABSTEIN  ET  AL.  1407 
PMA-stimulated EL4 thymoma cells. BSF-1 activity was extracted from crude supernatants 
by adsorption to trimethylsilyl-silica (C-l, Sepralyte; Analytichem International, Harbor 
City, CA) as previously described (19), with modifications. Crude supernatant was acidified 
with  0.1%  trifluoroacetic acid (TFA), and trimethylsilyl (TMS)-silica added (10 g/liter). 
After stirring  1.5  h,  the  supernatant was decanted.  The TMS-silica was poured into a 
column, washed with  20% acetonitrile with  0.1%  TFA, and the BSF-1  was eluted  with 
75% acetonitrile and 0.1%  TFA.  Acetonitrile was removed by rotary evaporation, and 
the aqueous phase was adjusted to 5 mM sodium citrate, 50 mM NaC1, pH 5.5. 
The TMS-silica-purified BSF-1  was fractionated on carboxymethyl cellulose (CM52; 
Whatman,  Inc., Clifton, NJ).  BSF-I  bound and was eluted with a  linear NaCI gradient. 
The fractions containing BSF-1  were pooled, dialyzed against 20 mM Tris, pH 9.0, and 
fractionated on quarternary aminoethyl cellulose (QA52, Whatman, Inc.) to which BSF- 
1 bound, and was eluted with a linear NaCI gradient. 
Reversed-phase HPLC fractionation of partially purified BSF-1  preparations was per- 
formed on a 4.6 x 250 mm Vydac 218TP (C,s) column (The Separations Group, Hesperia, 
CA) using a  Beckman Model 344 solvent delivery system. For purification step HPLC I 
(Table  I), the  column  was equilibrated  with  0.1%  TFA in  water at a  flow rate of 0.8 
ml/min. Fractions containing BSF-1 activity from the QA52 column were pooled, adjusted 
to  pH  2  with  TFA,  and  injected  onto  the  column.  The  column  was  washed  for  10 
additional  minutes with  0.1%  TFA and  then  brought to  10%  acetonitrile (containing 
0.1% TFA) over 2 min. After an additional 8 min of equilibration at 10% acetonitrile, a 
linear gradient from 10 to 70% acetonitrile in 0.1% TFA was run over 60 min (1% per 
minute), and  1-min fractions were collected. 
For HPLC If, active fractions from HPLC I were pooled and concentrated in vacuo to 
250 ul, and injected onto the same column, equilibrated with 50 mM acetic acid adjusted 
to  pH  4.50  with  N,N-diisopropylethylamine (DIEA-Ac), at a  flow rate of 0.7  ml/min. 
After a 5 min wash with DIEA-Ac, the column was brought to 5% n-propanol over 2 min. 
After an additional  8  min  of washing,  a  linear gradient from 5  to 40%  n-propanol in 
DIEA-Ac over 70 min (0.5%/rain) was run, and  1 min fractions were collected. 
N-terminal Protein Sequencing.  Amino-terminal amino acid sequencing was performed 
on an Applied Biosystems Model 470A protein sequencer (Applied Biosystems Inc., Foster 
City,  CA).  Homogeneous  BSF-1  from  HPLC  II  fractions  61  and  62  (Fig.  1)  were 
concentrated  in  vacuo to a  final volume of 30 /zl and then  spotted onto a  conditioned 
sequencer filter.  Sequencing and  PTH amino acid analysis was performed as described 
previously (20). 
SDS-PAGE.  Fractions from the purification steps were monitored by SDS-PAGE and 
subsequent silver staining, as described previously (2 I). 
Results 
InitialPur~cation.  BSF-1 was purified from serum-free supernatants of PHA- 
and PMA-stimulated EL4 cells as described in Materials and Methods and Table 
I.  BSF-1  was  extracted  from  crude  supernatants  by adsorption  to  TMS-silica. 
BSF-1 was eluted in TFA/acetonitrile, and further fractionated by a combination 
of cation- (CM52) and anion- (QA52) exchange chromatography (Table I). 
HPLC.  Biologically  active  fractions  eluted  from  the  QA52  column  were 
pooled and  fractionated  by HPLC on  a  C18  column as described  in  Materials 
and  Methods.  After  one  fractionation  using  a  TFA/acetonitrile  buffer  system 
(HPLC I), an  intense  band at  18.4  kD was detected  by silver staining on  SDS- 
PAGE gels (Fig.  1,  lane  1, SM), which  correlated with BSF-1  biological activity. 
BSF-l  biological activity was eluted from the HPLC column in 42% acetonitrile. 
The biologically active fractions from HPLC I were further fractionated using 
the same HPLC column equilibrated  in a  different buffer system (see Materials 
and Methods).  As shown in Fig.  l, this fractionation yielded homogeneous BSF- 1408  PURIFICATION  OF  B  CELL  STIMULATING  FACTOR 
TABLE  I 
Pur~cation of BSF-1 
Total  Specific  Yield 
Step  activity  activity 
U x  10 -6  U/ug  % 
Crude  21.4  3  100 
TMS-silica  19.7  100  92 
CM52  13.7  2,500  64 
QA52  5.6  26,000  26 
HPLC I  5.1  127,100  24 
HPLC II  1.6  328,000  8 
BSF-1 was purified from 71.5 liters of crude EL4 supernatant as described 
in Materials and Methods. Units of BSF-1  activity were determined using 
purified B cells.  Protein was measured using the Bradford protein assay 
(BioRad Laboratories, Richmond, CA). 
1 protein as detected by silver-stained SDS-PAGE, and as confirmed by protein 
sequencing.  The  peak  of BSF-1  biological  activity  eluted  at  32%  n-propanol. 
Although acceptable yields of protein  were recovered at this step, some loss of 
biological activity was observed, which possibly was due to denaturation  of the 
BSF-1 molecule in the propanol  solvent. The observed sp act of this BSF-1  was 
3.28 x  l0 w  U/rag. 
Protein Sequencing.  Fractions 61  and 62 (Fig.  1) from the HPLC II-purified 
preparation  were  subjected  to  amino-terminal  protein  sequencing.  Only  one 
sequence was obtained,  consistent  with  the  preparation  of BSF-1  having  been 
purified to homogeneity. The yields for each cycle ofamino-terminM sequencing 
are shown in  Table II. The initial  yield, 56%,  is based upon isoleucine in cycle 
two, due to typically poor yields for histidine residues (cycle one). The absolute 
yield of 67.4 pmol  isoleucine in cycle two is consistent with  the expected yield 
(50-70%) from the  120 pmol (2.2 #g) of BSF-1 applied to the sequencer filter. 
The first 20 residues,  His-Ile-His-Gly-Cys-Asp-Lys-Asn-His-Leu-Arg-Glu-Ile-Ile- 
Gly-Ile-l,eu-Asn-Glu-Val,  were found to be a  unique sequence when compared 
to  previously  published  reports  (22).  The  assignment  of Cys  to  position  5  is 
tentative,  since  no  signal  was  observed  for  cycle  5  and  the  protein  was  not 
modified before sequencing. 
Biological Activity.  All fractions throughout  the purification  were simultane- 
ously  monitored  for  BSF-1,  IL-2  (CTLL  proliferation),  and  IL-3  (FDC-P2 
proliferation) activities. The majority of IL-2, as measured by CTLL prolifera- 
tion, separated from BSF-1 on the CM52 column. However, subsequent to that 
step, all CTLL activity eluted precisely with the BSF-1 activity. EL4 supernatants 
contained no IL-3 protein, and all FDC-P2 activity eluted with BSF-1. The CTLL 
and FDC-P2 cell line response assays, using HPLC-purified BSF-1  fractions, are 
shown in Fig. 2. It is clear that purified BSF-1 has the capacity to score positively 
in both conventional IL-2 and II.-3 assays. 
As seen in  Fig.  3, several factor-dependent cell lines were compared for their 
responses  to  IL-2,  IL-3,  and  BSF-1.  CTLL,  FDC-P2,  and  32D all  respond  to 
BSF-1, but to a  lesser extent (a  lower maximum  incorporation  and  a shallower 
slope) than  to either IL-2 or II.-3. GRABSTEIN  ET  AL.  1409 
FIGURE  1.  Purification of BSF-1 by HPLC.  HPLC fractions from the final purification step 
(HPLC 11) shown in Table I were assayed for BSF-1 activity (top) and analyzed by SDS-PAGE 
(bottom)  as described in Materials and Methods. SM (starting material) in lane I  is the pool of 
aclive fractions from HPLC I. 
Discussion 
We have purified murine BSF-I  to homogeneity from supernatants  of stimu- 
lated  EL4  thymoma  cells,  and  have  determined  its amino-terminal  amino  acid 
sequence. Homogeneous BSF-I  was found to have a  molecular mass of 18.4 kD, 
with a sp act of at least 3.28 x  10  s U/rag. In addition, this lymphokine was found 
to stimulate the proliferation of both IL-2- and IL-3-dependent cell lines. 
BSF-1  was  originally described as  B  cell  growth  factor because it stimulated 
partially purified splenic B lymphocytes to proliferate in  the presence of submi- 
togenic concentrations of goat anti-mouse  IgM  (7).  However, recent evidence 1410  PURIFICATION  OF  B CELL STIMULATING  FACTOR 
TABLE II 
Protein Sequence  from Purified Murine BSF-I 
Amino 
acid 
Ash 
Ser 
Thr 
Gin 
Gly 
His 
Ala 
Asp 
Arg 
Glu 
Tyr 
Val 
Pro 
Met 
lie 
Leu 
Phe 
Trp 
Lys 
Cys 
1  2  3  4  5  6  7 
{4.6  --  26.2 
67.4 
23.4 
m  m 
m  __ 
36.6 
()*  - 
37.3 
Yield (pmol) from cycle number: 
8  9 
45.5  -- 
19.6 
34.9 
10  11  12  13  14  15  16  17  18  19  20 
--  23.5 
__  m 
17.3 
248 
22.7  17.1 
30.5  41.4  11.4  34.7 
31.3 
26.6 
Sequence  assigned  to first 20 amino acids of BSF-1  is:  His-I•e-His-G•y-Cys-As•-Lys-Asn-His-Leu-Arg•Glu-I•e-•le-Gly-I•e-Leu-Asn-Glu-Va•• 
* Values <10 pmol are omitted for clarity. 
~; Assigned as Cys due to lack of other signals; sulfhydryl  groups  were not modified  before sequencing. 
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FIGURE  2.  Assay  of HPLC  II  fractions  on  CTLL  and  FDC-P2  ceils.  HPLC  fractions  from 
the  final  purification  step  (HPLC  II) shown  in  Table  I  and  Fig.  1  were  assayed  in  the  CTLL 
and  FDC°P2  proliferation  assays as described  in  Materials  and  Methods. 
(10,  11) suggests  that semipurified BSF-1  is not a direct growth  factor for small 
resting  B  cells,  but  rather  primes  them  for subsequent  entry  into  S  pbase  on 
encounter  with anti-IgM,  indicating  that  BSF-1  is a  differentiation  factor.  Con- 
sistent  with  this  role  of  BSF-1  are  the  findings  that  partially  purified  BSF-1 
induces the cell surface expression  of Ia on B cells (23,  24), and the secretion of 
IgG 1 by LPS-activated  B cells (25-27).  Roehm et al. (24) have also observed that 
partially purified BSF-1  augments  the antigen-presenting  function of B cells. 
Our observation  that  BSF-1  directly stimulates  proliferation  of IL-2- and  IL- GRABSTEIN  ET  AL.  1411 
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FIGURE  3.  Response of B cells and factor-dependent cell lines to homogeneous lymphokines. 
Homogeneous BSF-1  (I--1), rIL-2 (A), and rIL-3 (O) were tested for the stimulation of purified 
B  cells (A),  FDC-P2  (B),  32D  (C),  and  CTLL  (D)  as described  in  Materials  and  Methods. 
Threefold dilutions of each lymphokine were tested starting at 500 U/ml and results reported 
incpmx  10 -~. 
3-dependent  cell  lines  indicates  that  BSF-1  is  a  growth  factor  as  well  as  a 
differentiation factor. This should not be surprising, as similar results have been 
obtained in studies of other lymphokines. For example, IL-2 stimulates prolif- 
eration of T  cells,  however, it has recently become evident that IL-2 also elicits 
a  variety  of differentiated T  cell  functions (28-30).  Moreover,  granulocyte- 
macrophage-CSF (GM-CSF) has also been shown to activate differentiated mac- 
rophage (31) and granulocyte (32) effector functions, in addition to its traditional 
growth-stimulating activity on myeloid stem cells in the marrow. 
Lymphokines that act on multiple lineages of cells are not without precedent. 
IL-2, once thought to act only on T  lymphocytes, has recently (3, 4) been shown 
to drive  proliferation of B  cells  as  well.  Additionally, several  IL-3-dependent 
nonlymphoid cell lines have also been shown capable of responding to IL-2 (33, 
34).  Sanderson et al. (35) have reported that another B cell stimulating factor, 
BCGF-II, also acts as an eosinophil differentiation factor. One important caveat 
remains:  although  we  have  shown  that  BSF-1  stimulates  non-B  cell,  factor- 
dependent cell  lines  to  proliferate,  it  has  yet to  be  determined whether this 
reflects a  role of BSF-1  on normal cel[s,  or whether those responses represent 
abnormal capabilities on the part of cells maintained in vitro for extended periods 
of time. 
The ability of BSF-1  to act on  IL-2- and  IL-3-dependent cell lines suggests 
that BSF-1  has target cells beyond the B cell lineage, and may have significant 
functions other than the regulation of B cell growth and maturation. 
Summary 
Murine B cell stimulating factor 1 (BSF-1)  was purified to homogeneity from 
supernatants of a  stimulated thymoma cell  line.  A  protein  of 18.4  kD  with a 
unique N-terminal amino acid sequence was identified. BSF-1  had asp act of at 
least 3.28 ×  108 U/mg. In addition to its B cell-stimulatory activity, BSF-1  also 1412  PURIFICATION OF  B  CEI.L STIMULATING  FACTOR 
stimulated  the  proliferation  of several  IL-2- and  IL-3-dependent  cell  lines.  We 
conclude that BSF-1  is both a growth factor and a differentiation  factor.  Finally, 
these  results  also  suggest  additional  biologic  properties  of  BSF-1  on  lineages 
besides  B lymphocytes. 
We  gratefully  acknowledge  the  technical  contributions  of Carol  Ramthun,  Elizabeth 
Conrad, and Elizabeth McGrath, and we thank Judy Byce for typing the manuscript. 
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